Liu Mengyuan, Ren Kexing, Ai Ping, Zou Liqun
Department of Radiation Oncology, Department of Head and Neck Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Department of Medical Oncology, Cancer Center, West China Hospital of Sichuan University, Chengdu, China.
Front Oncol. 2024 Aug 5;14:1419145. doi: 10.3389/fonc.2024.1419145. eCollection 2024.
This case report describes a 16-year-old patient with refractory Hodgkin's lymphoma who developed bilateral anterior and intermediate uveitis as an adverse reaction to Brentuximab vedotin (BV). This is a rare case of an ocular adverse reaction potentially related to BV, with symptoms like blurred vision, decreased visual acuity, photophobia, and redness. Potential mechanisms include BV targeting CD30+ T cells in the uveal tissue or an immune response triggered by the microtubule-disrupting agent MMAE within BV. This highlights the need for vigilant monitoring of ocular adverse events in BV-treated patients and further research into their mechanisms and management.
本病例报告描述了一名16岁难治性霍奇金淋巴瘤患者，其在接受维布妥昔单抗（BV）治疗时出现双侧前葡萄膜炎和中间葡萄膜炎，作为不良反应。这是一例罕见的可能与BV相关的眼部不良反应病例，症状包括视力模糊、视力下降、畏光和眼红。潜在机制包括BV靶向葡萄膜组织中的CD30+ T细胞或BV内微管破坏剂MMAE引发的免疫反应。这凸显了对接受BV治疗的患者进行眼部不良事件密切监测以及对其机制和管理进行进一步研究的必要性。
